Navigation Links
Photo: Welchol(TM) (colesevelam HCl) Receives FDA Approval to Reduce Blood Glucose in Adults with Type 2 Diabetes
Date:1/22/2008

First and only medication approved to reduce both A1C and LDL cholesterol

PARSIPPANY, N.J., Jan. 22 /PRNewswire/ -- Daiichi Sankyo, Inc., announced that the United States Food and Drug Administration (FDA) has approved Welchol(TM) (colesevelam HCl) to improve glycemic control (measured as hemoglobin A1C) in adults with type 2 diabetes mellitus in combination with metformin, sulfonylureas, or insulin, either alone or in combination with other anti-diabetic agents. Welchol is now the first and only medication approved to reduce both glucose levels and low density lipoprotein cholesterol levels (LDL-C). The ADA estimates that 20.8 million people in the United States have diabetes with more than 90 percent of these people having type 2 diabetes.(1) Forty percent of patients with type 2 diabetes also have high LDL-cholesterol.(2) Welchol is a new option that addresses both these chronic health conditions and provides physicians with a unique therapeutic approach for treating patients with type 2 diabetes.
(Photo: http://www.newscom.com/cgi-bin/prnh/20080122/NYTU059 )

To view the Multimedia News Release, go to:

http://www.prnewswire.com/mnr/welchol/29889/

Pivotal data presented at the American Diabetes Association's (ADA) 67TH Annual Scientific Sessions in Chicago in June, 2007 demonstrated that Welchol can lower both A1C and LDL-C levels in patients with type 2 diabetes who were uncontrolled on a metformin-based regimen. Patients in the study were randomly assigned to two groups. The addition of Welchol was compared to the addition of placebo in patients on a metformin-based regimen. The addition of Welchol (n=79) to pre-existing metformin monotherapy achieved a significant mean reduction in A1C levels of 0.47 percent relative to placebo (p<0.0024). Further, the total Welchol tr
'/>"/>

SOURCE Daiichi Sankyo, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
2. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
3. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
4. Abbott Receives Supplemental FDA Approval for its Best-in-Class in Sensitivity RealTime HIV-1 Viral Load Test
5. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
6. CryoCor Receives FDA Approval for Right Atrial Flutter
7. Ranbaxy Receives Approval to Manufacture and Market Hydrocodone Bitartrate and Acetaminophen Tablets USP
8. Dimericine(R) Receives FDA Fast Track Designation for Treatment Of Photosensitivity in XP Patients
9. Poniard Pharmaceuticals Receives FDA Fast Track Designation for Picoplatin for Treatment of Small Cell Lung Cancer
10. Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma
11. The Female Health Company Receives USAID DELIVER PROJECT Order for 5 Million Units
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2008)...Assess Survival of Patients Receiving Litx versus ...cellular Carcinoma , , BELLEVUE, Wash., Nov... (LSO) today announced the completion of enrollmen...sion Therapy(TM) (Litx(TM)) as a treatment for unr...wn as hepatoma or primary liver cancer. , , ...
(Date:11/24/2008)... Takeda Pharmaceutical Company Limi... Research & Development Center, Inc., U.S., an...e of the U.S. Food and Drug Administration (FDA) r...e treatment of hyperuricemia in patients with gout...th one panel member abstaining. The vote followed ...
(Date:11/24/2008)...Call/ -- Leaders of Schering-Plough Corporation (N...s on the company,s research pipeline, highlighting...new entities in clinical trials or under regulator... "Research and development is adding strength and ...sformation," said Fred Hassan, chairman and CEO. ...
(Date:11/24/2008)... and long-term commitment to hepatitis research ,...stCall/ -- Schering-Plough Corporation (NYSE: SG..., its lead investigational oral hepatitis C protea...The company believes boceprevir has the potential ...inhibitor for treating chronic hepatitis C. The c...
Breaking Medicine Technology:Light Sciences Oncology Completes Patient Enrollment in Phase 3 Clinical Trial of Litx as a Treatment for Hepatocellular Carcinoma 2Light Sciences Oncology Completes Patient Enrollment in Phase 3 Clinical Trial of Litx as a Treatment for Hepatocellular Carcinoma 3Light Sciences Oncology Completes Patient Enrollment in Phase 3 Clinical Trial of Litx as a Treatment for Hepatocellular Carcinoma 4Arthritis Advisory Committee Recommends FDA Approval of Febuxostat for the Treatment of Hyperuricemia in Patients With Gout 2Arthritis Advisory Committee Recommends FDA Approval of Febuxostat for the Treatment of Hyperuricemia in Patients With Gout 3Schering-Plough Highlights R&D Pipeline Progress, Innovation and Breadth of Research Projects 2Schering-Plough Highlights R&D Pipeline Progress, Innovation and Breadth of Research Projects 3Schering-Plough Highlights R&D Pipeline Progress, Innovation and Breadth of Research Projects 4Schering-Plough Highlights R&D Pipeline Progress, Innovation and Breadth of Research Projects 5Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 2Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 3Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 4Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 5Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 6Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 7Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 8Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 9AIDS Stopped in Haiti Before U S 4956 1AIDS Stopped in Haiti Before U S 4956 2AIDS Stopped in Haiti Before U S 4956 3Neurobiological Technologies Announces Pricing of Its 2460 Million Common Stock Offering 1579 1Neurobiological Technologies Announces Pricing of Its 2460 Million Common Stock Offering 1579 2Oncolytics Biotech Inc Announces 2007 Third Quarter Results 1576 1Oncolytics Biotech Inc Announces 2007 Third Quarter Results 1576 2Oncolytics Biotech Inc Announces 2007 Third Quarter Results 1576 3Oncolytics Biotech Inc Announces 2007 Third Quarter Results 1576 4Oncolytics Biotech Inc Announces 2007 Third Quarter Results 1576 5Oncolytics Biotech Inc Announces 2007 Third Quarter Results 1576 6Oncolytics Biotech Inc Announces 2007 Third Quarter Results 1576 7Oncolytics Biotech Inc Announces 2007 Third Quarter Results 1576 8Oncolytics Biotech Inc Announces 2007 Third Quarter Results 1576 9Oncolytics Biotech Inc Announces 2007 Third Quarter Results 1576 10Oncolytics Biotech Inc Announces 2007 Third Quarter Results 1576 11Oncolytics Biotech Inc Announces 2007 Third Quarter Results 1576 12Oncolytics Biotech Inc Announces 2007 Third Quarter Results 1576 13Oncolytics Biotech Inc Announces 2007 Third Quarter Results 1576 14Oncolytics Biotech Inc Announces 2007 Third Quarter Results 1576 15Oncolytics Biotech Inc Announces 2007 Third Quarter Results 1576 16Oncolytics Biotech Inc Announces 2007 Third Quarter Results 1576 17Oncolytics Biotech Inc Announces 2007 Third Quarter Results 1576 18Oncolytics Biotech Inc Announces 2007 Third Quarter Results 1576 19Oncolytics Biotech Inc Announces 2007 Third Quarter Results 1576 20Oncolytics Biotech Inc Announces 2007 Third Quarter Results 1576 21Oncolytics Biotech Inc Announces 2007 Third Quarter Results 1576 22Oncolytics Biotech Inc Announces 2007 Third Quarter Results 1576 23Oncolytics Biotech Inc Announces 2007 Third Quarter Results 1576 24Oncolytics Biotech Inc Announces 2007 Third Quarter Results 1576 25Oncolytics Biotech Inc Announces 2007 Third Quarter Results 1576 26Oncolytics Biotech Inc Announces 2007 Third Quarter Results 1576 27Oncolytics Biotech Inc Announces 2007 Third Quarter Results 1576 28Oncolytics Biotech Inc Announces 2007 Third Quarter Results 1576 29ViroPharma Incorporated Reports Third Quarter and Nine Month 2007 Financial Results 4954 1ViroPharma Incorporated Reports Third Quarter and Nine Month 2007 Financial Results 4954 2ViroPharma Incorporated Reports Third Quarter and Nine Month 2007 Financial Results 4954 3ViroPharma Incorporated Reports Third Quarter and Nine Month 2007 Financial Results 4954 4ViroPharma Incorporated Reports Third Quarter and Nine Month 2007 Financial Results 4954 5ViroPharma Incorporated Reports Third Quarter and Nine Month 2007 Financial Results 4954 6ViroPharma Incorporated Reports Third Quarter and Nine Month 2007 Financial Results 4954 7ViroPharma Incorporated Reports Third Quarter and Nine Month 2007 Financial Results 4954 8ViroPharma Incorporated Reports Third Quarter and Nine Month 2007 Financial Results 4954 9ViroPharma Incorporated Reports Third Quarter and Nine Month 2007 Financial Results 4954 10
... BOULDER, Colo.--(BUSINESS WIRE)--Jun 20, 2007 - A...hase 1 clinical data on its MEK,inhibitor, ARRY-16...were presented at the Annual European Congress of ...he International Association,of Inflammation Socie... Copenhagen, Denmark., ARRY-162 / MEK Inhibitor Ph...
... VIENNA, Va., June 20, 2007 /PRNewswire/ -- Modig... successful completion of,pharmacokinetic and phar...ng human growth hormone, long-acting interferon be...armacodynamic and pharmacokinetic pre-clinical,exp...g-acting,proteins, indicating a potential administ...
Other Medicine Technology:Array BioPharma Reports New Clinical Data on Its Anti-Inflammatory,Drugs 2Array BioPharma Reports New Clinical Data on Its Anti-Inflammatory,Drugs 3Array BioPharma Reports New Clinical Data on Its Anti-Inflammatory,Drugs 4Modigene Announces Successful Completion of Pharmacokinetic &,Pharmacodynamic Pre-Clinical Experiments for Proprietary,Long-Acting Human Growth Hormone, Long-acting Interferon Beta and,Long-acting Erythropoietin 2Modigene Announces Successful Completion of Pharmacokinetic &,Pharmacodynamic Pre-Clinical Experiments for Proprietary,Long-Acting Human Growth Hormone, Long-acting Interferon Beta and,Long-acting Erythropoietin 3Modigene Announces Successful Completion of Pharmacokinetic &,Pharmacodynamic Pre-Clinical Experiments for Proprietary,Long-Acting Human Growth Hormone, Long-acting Interferon Beta and,Long-acting Erythropoietin 4
(Date:12/1/2008)...rstCall/ -- Senetek PLC,(OTC Bulletin Board: SNKT...pment of technologies that target the science of h... AG, specialists in the fields of strategic,devel... offices in Zurich,Bern and Geneva has published...search Report, available in the "Investors" sectio...
(Date:12/1/2008)...against plantar fasciitis, researchers say , ...n researchers say they,ve developed a fast, effect...ondition known as plantar fasciitis. , Using a ...ns guided by ultrasound, the researchers say their...ckling a condition that afflicts about one million...
(Date:12/1/2008)...ohnson Public Service Announcement (PSA) focuses o... PARK, Ill., Dec. 1 T...he Magic Johnson Foundation and Abbott are cal...mily and friends about HIV/AIDS and its impact on ...rking tool allows Facebook users to stand with Mag...
(Date:12/1/2008)...e Cross Blue Shield of Michigan,provided more tha...nformation,today to Michigan Attorney General Mik...on about Michigan,s individual health insurance ma...n,s individual health insurance market,and escala...,s last-resort,insurance carrier, in its individu...
Breaking Medicine News(10 mins):Health News:New Twist on Treatment of Foot Pain 2Health News:New Twist on Treatment of Foot Pain 3Health News:Video: Magic Johnson Foundation and Abbott Call for Greater Prevention, Testing and Treatment on World AIDS Day 2Health News:Video: Magic Johnson Foundation and Abbott Call for Greater Prevention, Testing and Treatment on World AIDS Day 3Health News:Video: Magic Johnson Foundation and Abbott Call for Greater Prevention, Testing and Treatment on World AIDS Day 4Health News:Video: Magic Johnson Foundation and Abbott Call for Greater Prevention, Testing and Treatment on World AIDS Day 5Health News:Blue Cross Blue Shield of Michigan Answers Attorney General 2Health News:Blue Cross Blue Shield of Michigan Answers Attorney General 3
... by addiction specialists and published in Lancet ...trimental to health than class A drugs. Prof David.... This study rates alcohol as the fifth most da...d and safety. Tobacco is considered more addictiv...
...disease tuberculosis is on the march. Figures rele...an increase by 2 percent in number of TB cases ove...orld TB Day, which falls on the 24th of March, a...ngland, Wales and Northern Ireland. London contin...
...ening Committee of UK are considering ways to regu...According to Sir Muir Gray, program director of th...ence of these screening programs creating unwant...tant pressure being put on the National Health Ser...
.... Steriani Elavsky, women passing through their me...ife// when they exercised. The improvements in hea...tive effect on their perceived quality of life. T...tive menopausal women who were divided into three ...
Other Medicine News:Health News:TB Cases on the Rise 2
Inquire
Inquire
Hydragel K20 is Sebia's quality line of manual agarose gel electrophoresis products. Samples are applied utilizing the same patented applicator combs that is used for sample application on the HYDRAS
...ew device for skin extension.Thanks to its titaniu...ws a constant and powerful creep reaction of the t... effectiveness makes the FRECHET EXTENDER® a s...ys. Furthermore it is invisible when implanted. Ma...
Medicine Products: